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study question:What are the in vitro effects of estrogen receptor b (ERb) activation on the function of endothelial cells (ECs) from dif-
ferent vascular beds: human endometrial ECs (HEECs; endometrium), uterine myometrial microvascular ECs (UtMVECs; myometrium) and
human umbilical vein ECs (HUVECs)?
summaryanswer: Studies conducted in vitro demonstrate that the ERb agonist 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN) has EC
type-speciﬁc effects on patterns of gene expression and network formation. Identiﬁcation of a key role for the transcription factor Sp1 in ERb-
dependent signaling in uterine ECs offers new insights into cell-speciﬁc molecular mechanisms of estrogen action in the human uterus.
what is knownalready: Estrogens, acting via ERs (ERa andERb), have important, body-wide impacts on the vasculature.Thehuman
uterus is anestrogen targetorgan, theendometrial liningofwhich exhibits physiological, cyclical angiogenesis. In ﬁxed tissue sections, humanendo-
metrial ECs are immunopositive for ERb.
studydesign, size, duration: Cellswere treatedwith a vehicle control or the ERb agonist,DPN, for 2 hor 24 h (n ¼ 5) followedby
gene expression analysis. Functional assays were analyzed after a 16 h incubation with ligand (n ¼ 5).
participant/materials, setting, methods: Analysis of DPN-treated ECs using Taqman gene array cards focused on genes
involved in angiogenesis and inﬂammation identiﬁed cell type-speciﬁc ERb-dependent changes in gene expression,with validation using qPCR and
immunohistochemistry. Molecular mechanisms involved in ERb signaling were investigated using bioinformatics, reporter assays, immunopreci-
pitation, siRNA and a speciﬁc inhibitor blocking Sp1-binding sites. The endometrium and myometrium from women with regular menses were
used to validate the protein expression of candidate genes.
main results and the role of chance: HEECs and UtMVECs were ERb+/ERa2. Treatment of ECs with DPN had opposite
effects on network formation: a decrease in network formation in HEECs (P ≤ 0.001) but an increase in UtMVECs (P ≤ 0.05). Genomic analysis
identiﬁed opposite changes in ERb target gene expression with only three common transcripts (HEY1, ICAM1, CASP1) in all three ECs; a unique
proﬁlewas observed for each. An important role for Sp1was identiﬁed, consistentwith the regulation of ERb target genes via associationwith the
transcription factor (‘tethered’ mechanism).
limitations, reasons for caution: The study was mainly carried out in vitro using ECs of which one type was immortalized.
Although the analysis of the protein expression of candidate genes was carried out using intact tissue samples from patients, investigations
into in vivo angiogenesis were not carried out.
wider implications of the findings: These results have implications for our understanding of the mechanisms responsible for
ERb-dependent changes in EC gene expression in hormone-dependent disorders.
study funding/competeing interest(s): The study was funded by aMedical ResearchCouncil ProgrammeGrant. E.G. is the
recipient of an MRC Career Development Fellowship. The authors have nothing to disclose.
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Estrogens have body-wide effects and are essential regulators of repro-
ductive function in part bymodulating keyprocesses such as angiogenesis
and inﬂammation (Smith, 2001; Jabbour et al., 2009). Endothelial cells
(ECs) that line the interior surface of blood vessels are believed to be
direct targets for estrogen action. Notably, both positive and negative
effects of estrogenic ligands (natural and synthetic) on vascular function
have been reported. These include comparisons between the incidence
of vascular disease in men and women (Farhat et al., 1996; Vitale et al.,
2010), in women before and after the menopause (McCrohon et al.,
2000) and in women taking hormone replacement therapy (Yang and
Reckelhoff, 2011). Angiogenesis is tightly regulated during development
and in adulthood. In adults, physiological angiogenesis is a feature of re-
productive tissues subject to cyclical remodeling in response to sex ster-
oids (Jabbour et al., 2006) and is an essential component of normal
wound healing (Bao et al., 2009). In contrast, aberrant angiogenesis is
associated with disorders of the reproductive system (Smith, 2001)
and with tumour growth and metastasis (Weis and Cheresh, 2011).
The human uterus contains two distinct tissue layers, the outer mus-
cularmyometriumand the innermulti-cellular endometrium. In a normal
non-pregnant woman, both layers are exposed to cyclical variations in
circulating concentrations of estrogens arising from ovarian activity
(Abraham, 1974). The inner/luminal layer of the endometrium is shed
at the time of menses and regeneration, followed by growth of new
blood vessels, which is an essential feature of the estrogen-dominated
proliferative phase (Nayak and Brenner, 2002). There have been
conﬂicting reports of the impact of estrogenic ligands on endometrial
angiogenesis (Girling and Rogers, 2005). The limited number of studies
that havebeen carried out onpuriﬁed cell populations suggest that estro-
gens may stimulate angiogenic activity of both endometrial (Kayisli et al.,
2004) and myometrial ECs (Zaitseva et al., 2004), although the study on
myometrial ECs included cells isolated from women with ﬁbroids, a
patient group in which endometrial function may be disturbed
(Sunkara et al., 2010).
In the uterus as in other tissues, estrogen action is mediated by recep-
tors acting as ligand-activated nuclear transcription factors or as part of
membrane-associated signaling cascades (Heldring et al., 2007).
Estrogen-dependent changes in gene expression can be mediated by
binding of estrogen receptors (ERs) to DNA either directly via classical
mechanisms at estrogen response elements (EREs), or through tethered
(non-classical) associations with other transcription factors (e.g. Sp1,
Jun/Fos), involving half EREs and GC-rich or AP-1 regions, respectively
(O’Lone et al., 2004). Human ERs are the products of two genes ESR1
and ESR2 that encode the ERa and ERb proteins, respectively. These
ER subtypes exhibit differential temporal and spatial expression patterns
within reproductive tissues and these proﬁles have impacts on tissue
function (Gibson and Saunders, 2012). ERa and ERb have a similar ar-
rangement of domains including a highly conserved DNA-binding
domain and a ligand-binding domain (LBD; Matthews and Gustafsson,
2003). The LBD of both receptors has been crystallized and differences
in the size/shape of the ligand-binding pocket have led to the develop-
ment of synthetic subtype-selective ER agonists, examples include
4,4′,4′-(4-propyl-(1H)-pyrazole-1,3,5-tryl)trisphenol (PPT, ERa select-
ive) and 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN, ERb selective;
Sun et al., 2003). Ligand binding induces a conformational change in
the receptor, unique to the ligand–receptor combination. The resultant
3D structure determines which co-regulatory proteins are bound to the
complex; this can play an important role in determining whether target
gene expression is augmented or abrogated (Nilsson and Gustafsson,
2010). Additionally, a number of anti-estrogens that block receptor ac-
tivation have been developed, e.g. the anti-estrogen ICI 182780 (Fulves-
trant), which functions as an estrogen receptor down-regulator, it binds
ERa and ERb with high afﬁnity, blocks receptor dimerization and accel-
erates receptor degradation (Hermenegildo and Cano, 2000).
Studies on the relative contributions of ERa and ERb to body-wide
impacts of estrogens have revealed that ERa plays a key role in the regu-
lation of cell proliferation and stromal–epithelial interactions and that
co-expression of ERb in ERa-positive cells can alter the pattern of
gene expression (Gustafsson, 2003; Hewitt et al., 2005).
Studies have shown that ECs behave in a vascular bed speciﬁc manner
in response to locally derived signals (Rocha and Adams, 2009). This
implies that studies conducted on EC function must be carried out on
cells derived from the vascular bed of interest. As estrogen also exhibits
tissue selective effects, the commonly used human umbilical vein EC
(HUVEC) model could potentially be inappropriate to model uterine
EC function. To date, there is little evidence as to the function of ERb
when it is the sole ER subtype present in cells. We have previously
reported that endometrial ECs are ERb+/ERa2 (Critchley et al.,
2001) suggesting estrogen-dependent effects on their function are ERb
mediated.
The aim of the current study was to investigate the functional conse-
quence of ligand-dependent ERb activation in ECs from different com-
partments of the human uterus.
Materials andMethods
Cells and tissues
Three EC lines were used in the current study. The human endometrial ECs
(HEECs; gifted from Yale University) were originally isolated from human
endometrial microvessels using Ulex europaeus lectin (Schatz et al., 2000).
These cells were subsequently telomerase immortalized and a comparison
between theprimary and immortalized cells demonstrated that they retained
an identical phenotype including the expression of CD31, vonWillebrand’s
factor and the Tie-2 receptors (Schatz et al., 2000; Krikun et al., 2005a).
Primary uterine myometrial microvascular ECs (UtMVECs) were obtained
fromLonza (Walkersville, USA); these cells are guaranteed through15popu-
lation doublings and sold as CD31/105 and vonWilliebrand Factor VIII posi-
tive. HUVECs (gifted from T. Ramaesh, University of Edinburgh) are
commercially available primary ECs that are widely used for cell-based re-
search into factors regulating EC function. HUVECs were included in the
current studyas acontrol (non-uterine) EC.All ECsweremaintained in endo-
thelial growth media (EGM-2) (Lonza) supplemented with 10% fetal calf
serum(FCS) in ﬂasks coatedwith attachment factor (Gibco, Paisley,UK). Ishi-
kawa cells (endometrial adenocarcinoma cell line; European collection of cell
cultures (UK) were maintained in Dulbecco’s modiﬁed eagle’s medium
(Gibco) supplemented with 10% FCS, 2 mmol/l, L-Glutamine, antibiotics
and non-essential amino acids. Cells were cultured at 378C with 5% CO2;
at least 24 h prior to experiments, medium was changed to phenol
red-free media with 10% charcoal stripped FCS. Cells were stimulated with
1028 M 17b-estradiol (E2; Sigma, UK), the ERa-selective agonist PPT
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(Tocris, Bristol, UK) or the ERb-selective agonist DPN (Tocris) alone or in
combination with the anti-estrogen Fulvestrant—ICI 182 780 (ICI; 1027 M;
Tocris) dissolved in dimethylsulphoxide (DMSO). Full-thickness uterine
biopsy material used for immunohistochemistry (IHC) was obtained as pre-
viously described (Critchley et al., 2001).
Immunodetection
Immunocytochemistry was carried out on cells grown on chamber slides.
Cells were ﬁxed in ice-cold methanol for 10 min and then permeabilized in
a blocking solution containing 0.2% IGEPAL (Sigma-Aldrich). Non-speciﬁc
binding sites were blocked with a species-speciﬁc blocking solution [1:5
part normal serum in Tris-buffered saline (TBS)/5% bovine serum albumin
(BSA)] for 30 min. Endogenous streptavidin and biotin were blocked using
a kit available from Vector Laboratories. Primary antibodies were diluted in
blocking solution (Supplementary data, Table S3) and incubated overnight
at 48C. Biotinylated secondary antibodies (1:500) were diluted in 5% BSA
in TBS and incubated at room temperature (RT). A streptavidin–HRP con-
jugate (1:1000; Sigma-Aldrich) was diluted in TBS and used for incubation
atRT for 30min followedby visualizationwith ImmPACTTM DABperoxidase
substrate (Vector Laboratories). Cells were counterstained, dehydrated,
cleared in xylene and mounted in Pertex.
IHCwas carried out on parafﬁn-embedded full-thickness uterine sections.
Sections were dewaxed in xylene and rehydrated to water. Citrate antigen
retrieval was performed followed by endogenous peroxidase block with
3% H2O2 in methanol. Streptavidin–biotin block (Vector Laboratories)
was carried out followed by species-speciﬁc block and incubation with
primary antibodyovernight. Secondary antibody detection and counterstain-
ing were performed as above. For full-thickness sections, tiling was carried
out using Axiovision for Axiovert (Carl Zeiss). Dual immunoﬂuorescence
on parafﬁn-embedded full-thickness uterine sections was achieved by
dewaxing and rehydrating sections as before, then the antigen retrieval and
peroxidase block were performed followed by species-speciﬁc block. All
washes were carried out in PBS for ﬂorescent methods. Primary antibody
was diluted in blocking solution and incubated overnight at 48C.A secondary
F (ab) polyclonal antibody to IgG (HRP) was diluted in blocking solution and
incubated on sections for 30 min at RT. All subsequent washes included a
single wash with PBS containing 0.05% Tween and then a wash in PBS. Anti-
body detection was carried out using a TSATM system kit labelled with either
Cy3 (red) or ﬂuorescein (green; Perkin Elmer, Inc.) diluted 1:50 for 10 min.
For the detection of the second protein of interest, sections were
microwaved for 2.5 min in boiling citrate buffer, an additional species-speciﬁc
blockwas carriedout and the secondprimary antibodywas appliedovernight
at 48C. The secondary antibody was detected as before with the
appropriate TSA system and sections were counterstained with DAPI
(1:500) for 10 min. Slides were mounted in Permaﬂuor (Thermo Fisher Sci-
entiﬁc) and imaged using an LSM710 confocal microscope and AxioCam
camera (Carl Zeiss, Inc.).
ER proteins were detected using a mouse monoclonal raised against a
peptide present at the C-terminus of full-length wild-type ERb (ERb1;
Serotec, Kidlington, UK) but absent from splice variants of human ERb
(ERb2, ERb5; Critchley et al., 2002) and a mouse monoclonal speciﬁc for
ERa (Vector, Peterborough, UK). CD31 protein was detected using a
mousemonoclonal anti-CD31 (Dako,Cambridgeshire,UK).Candidate pro-
teins were detected using a rabbit polyclonal anti-IFNB1 (Epitomics, CA,
USA) and a rabbit monoclonal ICAM1 (Abcam, Cambridge, UK). More
details on antibody dilutions are available in Supplementary data, Table S3.
RNA extraction and cDNA synthesis
Total RNAwas extracted at 2 or 24 h post-stimulation with ligand using the
RNAeasy kit (QIAGEN, Crawley, UK) and cDNA was synthesized using
SuperScriptwVILOTM (Invitrogen, Paisley, UK) with a starting template con-
centration of 100 ng RNA.
Quantitative real-time PCR
Taqman array cards (TACs) for angiogenesis and inﬂammation gene signa-
tures (Applied Biosystems, CA, USA) were analyzed according to the man-
ufacturer’s instructions using Taqmanw Universal PCR mastermix (Applied
Biosystems). Additional real-time PCR reactions were performed using the
Roche Universal ProbeLibrary (Roche Applied Science, West Sussex, UK)
and Express qPCR Supermix (Invitrogen). qPCR was performed on a 7900
Fast Real-Time PCR machine with 18S as the endogenous control. Primer
sequences can be provided on request. Bioinformatics analysis was carried
out using MetacoreTM (GeneGo.Com).
Western blot analysis
Nuclear protein was prepared using aNuclear Extract Kit (ActiveMotif, CA,
USA) separated on a NuPAGEw Bis-Tris Gel (Invitrogen), transferred onto
polyvinylidene ﬂuoride (PVDF) membranes (Millipore) and probed with the
following antibodies: mouse polyclonal anti-ERb (Santa Cruz Biotechnology,
CA, USA), mouse monoclonal anti-ERa (Vector), mouse monoclonal
anti-Sp1 (Abcam), rabbit polyclonal anti-Laminb1 (Abcam)ormousemono-
clonal anti-Laminb1 (Abcam). For secondarydetection, goat anti-mouse IgG
(Alexa ﬂuor IR 680, InvitrogenMolecular Probes) and goat anti-rabbit IgG (IR
Dye 800 CW, LI-COR, NE, USA) were used at 1:10 000 dilution. Antibody
binding was visualized using infra-red imaging on an Odyssey imaging system
(LI-COR).
Network formation assay
ECswere plated at 25 000 cells per insert into transwells coatedwith phenol
red-free growth factor reduced Matrigel (BD Biosciences, Oxford, UK).
Where appropriate, the pure anti-estrogen Fulvestrant/Faslodexw (ICI)
was added into the upper chamber of media 1 h before the addition of
ligands. All ligands were added to the bottom chambers and cells were incu-
bated for 16 h at 378Cwith 5%CO2. To block binding of Sp1 to GC regions,
weusedMithramycinA (50 nM; Sigma).Cellswereﬁxed in ice-coldmethanol
for 20 min and brieﬂy stainedwith haematoxylin. The formation of networks
was visualized using an Axiovert microscope (Carl Zeiss, Germany), where
three independent ﬁelds of vision were captured at ×5 magniﬁcation for
each well. Network formation was quantiﬁed using ImageJ (NIH.gov) soft-
ware, with images converted to binary and the area of networks analyzed
using the ‘count particles’ option. Results were veriﬁed by counting the
number of closed polygons. The mean number of polygons per well was cal-
culated, followedby themean for each treatment. The fold change compared
with the vehicle control was plotted.
Immunoprecipitation
Total cell protein was extracted from HEECs treated with DMSO or DPN
(1028 M) for 24 h. Immunoprecipitations were performed using Dynabeads
protein G (Life Technologies) following the manufacturer’s instructions with
anti-ERb (Abcam)or rabbit IgG (Dako) as the control.Antibodieswere cross
linked to the Dynabeads using BS3 (Thermo Fisher Scientiﬁc) and samples
incubated with the cross-linked complex overnight at 48C. The input and
immunopreciptated proteins were resolved by SDS–PAGE electrophoresis
and transferred onto PVDF membranes. Complexes containing Sp1 were
detected by incubating membranes with mouse anti-Sp1 (Abcam) at 1:300
dilution and analyzed using the LICOR system as described above.
siRNA knockdown
ECs were transfected with a non-speciﬁc siRNA (negative) or a synthetic
siRNA directed to ERb or Sp1 (Ambion, Paisley, UK) at a ﬁnal concentration
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of 5 nMusingHiPerFect transfection reagent (QIAGEN). At 48 h after trans-
fection, cells were treated with ligand and harvested at 2 or 24 h post-
treatment. Depletion was conﬁrmed by qPCR.
Proliferation assay
ECswere plated into 96-well plates at 3000 cells/well and allowed to adhere
overnight. Cell mediumwas replaced with EGM-2 1% charcoal stripped FCS
for 3 h, followed by addition of ligands. Treatments were replaced three
times during the 72 h culture period. To assess proliferation, medium was
removed and replaced with a 1:5 ratio of CellTitre96Aqueous One Solution
Proliferation Reagent (Promega) and EGM-2 1%. After a 3 h incubation, the
formation of formazan was recorded by measuring the absorbance at
490 nm.
Luciferase reporter assays
Cells were plated at 1 × 105 per well into 24-well plates and left to adhere
overnight; for each luciferase experiment, a corresponding control plate
was set up allowing the analysis of protein levels for normalization. Cells
were infected with an adenoviral 3× ERE luciferase construct (in house de-
velopment) with a multiplicity of infection of 50, with 6 mg/ml Polybrene
(Sigma). For the adenoviral system, 24 h after incubation, cells were stimu-
lated with ligands (1028 M). Whole cell lysates were harvested 24 h after
the addition of ligand with Glo Lysis buffer (Promega). Lysates were trans-
ferred to luminometer plates and a 1:1 ratio of Bright-Glo reagent
(Promega) was added. Luminescence was measured using a Fluostar
OPTIMA plate-reader (BMG Labtech). Analysis of corresponding plates
was analyzed for protein concentration using the DC protein assay
(Bio-Rad), and reporter gene expression was corrected by protein levels.
Statistical analysis
Statistical analysis was carried out using a one-way analysis of variance fol-
lowed by a Neuman–Keuls post-comparison test or a two-tailed unpaired
Student t-test. For qPCR data, statistical analysis was carried out on trans-
formed data. *P, 0.05, **P, 0.01 and ***P, 0.001.
Ethical approval
In brief, a full-thickness uterine biopsy material was collected from women
undergoing hysterectomy. Written informed consent was provided by all
subjects and ethical approval for tissue collection was granted by the
Lothian research ethics committee. Patients had regular menstrual cycles
and were not taking exogenous hormones.
Results
Uterine ECs express ERb but not ERa
To extend and conﬁrm our previous observations, we used dual ﬂuor-
escent IHC to co-stain full-thickness uterine samples for ERb and the EC
marker CD31. ERb and CD31 were co-localized in ECs within the
endometrium and myometrium at all stages of the menstrual cycle
(Fig. 1A and B). Myometrial ECs appeared immunonegative for ERa
even when closely adjacent cells were CD31+ (Fig. 1C and D; Supple-
mentary data, Fig. S1A). Eight patient samples were analyzed in detail
(four proliferative stage and four secretory stage), all vessels were exam-
ined in each section of the myometrium and no CD31-positive cells
were found to express ERa. ERb+ ECs were readily detectable in all
uterine layers (Supplementary data, Fig. S1B). Cells derived frommicro-
vascular beds of the human endometrium (HEECs; Schatz et al., 2000;
Krikun et al., 2005a,b), myometrium (UtMVECs) and HUVECs were
characterized to conﬁrm their EC phenotype (Supplementary data,
Fig. S2). All EC models were ERb+/ERa2 at the level of mRNA
(Fig. 1E) and protein (Fig. 1F). Ishikawa cells were used as an ERa expres-
sing control to validate our antibodies and primers. These comprehen-
sive proﬁling studies conﬁrmed that uterine ECs recapitulated the
pattern of expression of ERs in their native vascular beds.
A selective ERb agonist has an endothelial
subtype-speciﬁc impact on angiogenesis
An in vitromodel of angiogenesis (the network formation assay)was used
to compare the impacts of E2 and the ERb-selective agonist DPN on
endothelial function. These studies revealed striking opposite impacts
of DPN on HEECs and UtMVECs with a signiﬁcant decrease in the
amount of networks formed by HEECs (Fig. 2A; n ¼ 6, P ≤ 0.001) and
a signiﬁcant increase in UtMVECs (Fig. 2B; n ¼ 6, P ≤ 0.05). In both,
the effectwas abrogatedby the additionof the pure anti-estrogen Fulves-
trant (ICI) and surprisingly the same concentration of E2 had no signiﬁ-
cant impact. In HUVECs, we found that E2 and DPN had no signiﬁcant
impact on network formation compared with the vehicle control;
however, there was a signiﬁcant decrease in network formation when
cells were treated with ligand plus ICI (Fig. 2C; n ¼ 6, P ≤ 0.01 and
P ≤ 0.001). In HEECs and HUVECs, treatment with DPN or E2
increased cell proliferation (Supplementary data, Fig. S3A and C); the
changes observed in UtMVECs were not signiﬁcant (Supplementary
data, Fig. S3B).
The ERb-selective agonist DPN induces
speciﬁc patterns of gene expression in
ECs derived from different vascular beds
Using targeted gene arrays, we compared changes in the expression of
genes implicated in the regulation of angiogenesis and inﬂammation in re-
sponse to treatment with DPN between uterine ECs and a widely used
EC model (HUVECs). DPN was used in TAC studies because this
subtype-selective ER agonist produced the most profound effect in the
above functional studies. We used two time points (2 and 24 h) to en-
compass both an early and later response to ERb activation in cells. Ana-
lysis of RNA recovered from cells incubated with or without ligand at
both time points resulted in the identiﬁcation of signiﬁcant (.1.5-fold)
changes in 22 of 92 genes associated with angiogenesis (Fig. 3A; n ¼ 3)
and in 14 of 92 genes associated with inﬂammation (Fig. 3B; n ¼ 3) as
analyszed using TAC. The complete lists of differentially regulated
genes in each cell type are given in Supplementary data, Tables S1 and
S2. Notably, there were very few ERb-dependent genes common to
more than one of the three cell lines and several of the shared ERb-
dependent genes identiﬁed were regulated in opposite directions in
HEECs and UtMVECs (Supplementary data, Table S1, Fig. 4). Analysis
of the angiogenesis gene set revealed that only the expression of
HEY1, a transcriptional repressor part of the Notch signaling family
was altered in response to DPN (24 h) in all three EC lines (Fig. 3A).
Two other genes were regulated in HEECs and UtMVECs but not in
HUVECs; thesewere interferonb-1 (IFNB1) and autotaxin/ectonucleo-
tide pyrophosphatase/phosphodiesterase 2 (ENPP2). Analysis using the
inﬂammation TAC array revealed two ERb-dependent transcripts
common to all three ECs: intercellular adhesion molecule 1 (ICAM1,
CD54) and Caspase 1 (CASP1); these were signiﬁcantly changed after
2 h in HEECs and 24 h in UtMVECs and HUVECs. We also observed
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Figure 1 ERb, but not ERa, is expressed in ECs in both the endometrium andmyometrium and in vitromodels retain the original phenotype. (A andB)
Dual immunoﬂuorescent staining for ERb (green) and CD31 (EC marker; red) was carried out on full-thickness uterine biopsies at different stages of the
menstrual cycle. Co-localization was observed in vessels in the endometrium (A) andmyometrium (B). Arrows indicate ECs. G, Gland. Scale bar is 20 mm.
(C andD)Dual immunoﬂuorescent staining for ERa (green) andCD31 (red) carried out on full-thickness sections at different stages of themenstrual cycle.
ECs were negative for ERa in the endometrium (C) and myometrium (D). Scale bar is 50 mm. (E) mRNAs encoding wild-type ERb (ERb1) and ERawere
both detected in human adenocarcinomacells (Ishikawa) but all three EC lines,HEECs,UtMVECs andHUVECs, only containedmeasurable concentrations
of ERbmRNAs. Values represent themean+ SEM analyzed in triplicate from three separate experiments. Results are normalized to Ishikawa cells, where
one replicatewas given the arbitrary value of 1. RQ, relative quantiﬁcation (*P,0.05, ***P,0.001). (F) Immunolocalization of ERa and ERb1 carried out on
cell lines grown on chamber slides—note only Ishikawa cells were ERa+. ERb was localized to cell nuclei in all cell types. Negative controls with primary
antibody omitted are shown as insets. Bar ¼ 50 mm.
ERb-dependent signaling and endothelial cell function 5
 at Edinburgh U







particular trends present within the data set. For example, genes asso-
ciated with prostaglandin synthesis were regulated in all three ECs. Al-
though this common pathway was found, common genes within the
pathway were not (Supplementary data, Table S2). To summarize,
only one gene associated with angiogenesis and two genes associated
with inﬂammation were regulated by DPN in all three EC lines. Interest-
ingly, we found that the pattern of expression of angiogenic genes corre-
latedwith our functional studies. For example, inHEECs,weobserved an
overall down-regulation in pro-angiogenic factors but an up-regulation in
angiogenesis inhibitors (Supplementary data, Table S1). This correlated
with our observed decrease in network formation in response to DPN.
However, in the UtMVECs, we observed an up-regulation in
pro-angiogenic factors and a down-regulation in inhibitors in response
to DPN, correlating with an increase in network formation.
To complement and extend the data gathered using the TAC arrays,
qRT–PCR validation experiments were carried out using additional cul-
tures of all three EC lines treated with DPN alone, DPN plus ICI, E2
alone, E2 plus ICI or the ERa-selective agonist PPT (n ¼ 5; Fig. 4, Supple-
mentary data S4 and S5). Changes in the expression of HEY1 detected
using TAC in response to DPN were conﬁrmed using qRT–PCR in
HEECs (signiﬁcantly reduced) and UtMVECs (signiﬁcantly increased).
In all cases, inclusion of ICI abrogated the change observed and inclusion
of PPT had no impact consistent with the lack of expression of ERa in
these cells (Supplementary data S4A). Treatment of cells with E2
induced the same changes as DPN in UtMVECs and HUVECs but
were opposite (increased expression) in HEECs (Supplementary data
S4A). qRT–PCR analysis of IFNB1 expression conﬁrmed TAC results
in HEECs (signiﬁcantly up-regulated by DPN or E2 at 24 h). In
UtMVECs, validation conﬁrmed signiﬁcant down-regulation of IFNB1
by E2 but not by DPN (Supplementary data S4B). In HUVECs, IFNB1
was signiﬁcantly up-regulated following incubation with DPN or E2 for
24 h (Fig. 4B, Supplementary data S4B); this had not initially been
detected using the TAC array.We were, therefore, able to recapitulate
results gained using TAC (angiogenesis) in additional experiments, with
the exception of IFNB1 in UtMVECs that was regulated by E2 alone
and not DPN.
Conﬁrmation of expression of ICAM1 in HEECs, UtMVECs and
HUVECs in response to E2 or DPN as detected by qRT–PCR revealed
Figure2 ERb activationhas speciﬁc andopposing effects on endometrial andmyometrial EC function. (A,B andC)Cellswereplatedonto growth factor
reduced matrigel and incubated with E2 or DPN (1028 M) in the presence or absence of the pure ER antagonist (ICI; 1027 M). The impact on network
formation in HEECs (A), UtMVECs (B) and HUVECs (C) was analyzed after 16 h. Images show representative photos taken from wells treated with
DPN (large images) or DMSO (inset) illustrating differences in the formation of networks. Scale bars are 200 mm. Values represent the mean+ SEM
from ﬁve separate experiments (*P,0.05, **P,0.01, ***P,0.001).
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additional time dependent but similar impacts of DPN and E2, no signiﬁ-
cant response to PPT and abrogation of responses in the presence of ICI
(Fig. 4C, Supplementary data Fig. S5A). qRT–PCR analysis of CASP1 in
HEECs (by E2) andHUVECs (by E2 andDPN) revealed an up-regulation
at 2 h in contrast to the down-regulation detected by TAC (inﬂamma-
tion; Supplementary data Fig. S5A); this may indicate that ERb-
dependent regulation of CASP1 is not as robust as other candidates. Val-
idation of CASP1 mirrored the TAC results for UtMVECs.
To complement studies using anti-estrogen, depletion of ERbmRNA
using siRNAwas carried out inHEECs (Supplementary data Fig. S6A); in-
cubation of ERb-depleted cells with DPN failed to induce the same sig-
niﬁcant changes inHEY1 and IFNB1mRNAs seen in cells incubatedwith a
control siRNA (Supplementary data Fig. S6B and C).
To extend investigations on the expression of IFNB1 and ICAM1, IHC
was performed on full-thickness uterine sections. Both proteins
were detected in CD31+ ECswithin the endometrium (Supplementary
data Fig. S7A and E; S7I and M) and myometrium (Supplementary data
Fig. S7B and F; Fig. S7J and N), during both phases of the cycle.
Both proteins were co-expressed with ERb in ECs as well as in other
uterine cell types including epithelial cells (Fig. S7 labelled G).
Bioinformatics identiﬁes Sp1 as a key
regulator of ERb-mediated gene
expression in ECs
Following the identiﬁcation of ERb-dependent changes in vascular func-
tion and associated changes in gene expression, additional studies were
directed at understanding the molecular mechanisms by which ERb
induces changes in gene transcription in response to ligand activation.
Endothelial and Ishikawa (control) cells were infected with an adenoviral
construct containing a luciferase reporter gene under the control of a
3×ERE promoter. In Ishikawa cells, reporter gene expression was
induced by E2, DPN and PPT and abrogated by the inclusion of ICI
(Supplementary data Fig. S8A). In contrast, there was no evidence of re-
porter gene activation in any of the ERb+ ECs (Fig. S8B–D). It has been
proposed that ERb-mediated transcription may involve ‘tethered’
mechanisms depending upon the recruitment of additional transcription
factors; therefore, bioinformatic analysis of genes identiﬁed on the array
cards was carried out. This revealed that 12 of 18 of the ERb-dependent
genes identiﬁed in HEECs, including HEY1, ICAM1 and ENPP2, were
associated with the transcription factor Sp1 (Fig. 5A). Western analysis
conﬁrmed the expression of Sp1 in all three ECs (Fig. 5B). Immunopre-
cipitation was performed on HEEC proteins using an anti-ERb antibody
with the detection of Sp1 in the complex conﬁrmed following western
blotting and probing the membrane with an anti-Sp1 antibody
(Fig. 5C). This demonstrated that ERb and Sp1 are bound together
within HEECs regardless of the presence of ligand.
InhibitionofSp1-dependentactivityabrogates
ERb-dependent changes in EC function
and gene expression
To investigate whether the ERb-dependent changes in gene expression
detected in ECwere Sp1 dependent, we carried out siRNA knockdown
experiments using HEECs. Partial knockdown of Sp1 mRNA was
achieved using a Sp1-speciﬁc siRNA (Fig. 5D); the resulting reduction
in the expression of Sp1 abrogated DPN-dependent changes in the ex-
pression of HEY1 and IFNB1 (Fig. 5E and F). To determine whether the
ERb-dependent decrease in network formation observed in HEECs
was also Sp1 dependent, cells were treated with Mithramycin A, an
anti-cancer drug that binds toGC-rich regions of chromatin andprevents
binding of Sp transcription factors. Mithramycin A alone had no impact
but the addition of Mithramycin A to cultures containing DPN rescued
the cells from the ERb-dependent decrease in network formation
(Fig. 5G and H).
Discussion
This study is a comparative analysis of the impact of ERb activation, via
the binding of an ERb agonist (DPN), on EC function and associated
gene expression changes inmicrovascular EC lines derived fromdifferent
vascular beds of the human uterus (HEECs and UtMVECs) and ECs
obtained from HUVECs. HUVECs were included in the current study
as they are used extensively in studies on EC function.
While the study does possess limitations because primary tissue was
not used,webelieve thatour results demonstrate anumberof novel ﬁnd-
ings. First, toour knowledge, this study is the ﬁrst todirectly compareECs
from the endometrium andmyometrium and to indicate opposing prop-
erties for the two. This indicates that ER selective agonists may have dis-
tinct effects in different vascular beds, which may have implications
for the therapeutic application of ER subtype-selective agonists in
hormone responsive disorders characterized by aberrant angiogenesis.
Secondly, our ﬁndings expand suggestions that ECs from different vascu-
lar beds exhibit unique phenotypes. Notably, we found little overlap in
the expression of genes associated with angiogenesis and inﬂammation
in the three ECs we analyzed, each of which demonstrated unique ERb-
dependent patterns of gene expression, suggesting that our cell models
retain the phenotype of their vascular origin. These results also suggest
that there may be no ‘ideal EC model’ in which to study ERb-mediated
changes in cell function and that assessment of the likely impacts of
Figure3 Incubation of ECswith DPN results in altered expression of
distinct subsets of genes in ECs derived from different vascular beds.
HEECs, UtMVECs and HUVECs were incubated with media containing
vehicle alone (control, DMSO) or DPN (1028 M in DMSO) for 2 or
24 h. A sample size of two from three separate experiments was gener-
ated foreach timepoint and cell line; all sampleswere analyzed in parallel
on TAC.Only genes thatwere subject to a statistically signiﬁcant change
following the treatment with DPN were reported. (A) Venn diagram
representing ERb-dependent genes associated with angiogenesis.
(B) Venn diagram representing ERb-dependent genes associated with
inﬂammation. Diagrams represent the sum of all up- and down-
regulated genes that showed statistically signiﬁcant changes at 2 or
24 h post-stimulation. Full gene lists are supplied in Supplementary
data, Tables S1 and S2. TAC, TaqMan array cards.
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Figure 4 ERb-dependent changes in gene expression are regulated in opposite directions in ECs derived from different vascular beds. qRT–PCR val-
idation of TAC results was carried out using Roche Universal ProbeLibrary (Roche Applied Science) with Express qPCR Supermix (Invitrogen) on HEECs,
UtMVECs and HUVECs, treated with the vehicle control (DMSO), DPN (1028 M) or DPN plus the anti-estrogen Fulvestrant (ICI, 1027 M). Values rep-
resent the mean+ SEM, n ¼ 5. Results are normalized to the vehicle control where one replicate was given the arbitrary value of 1. RQ, relative quanti-
ﬁcation (*P,0.05, **P,0.01, ***P,0.001). (A) HEY1 24 h (no impact at 2h ), (B) IFNB1, 2 and 24 h, (C) ICAM1, 2 and 24 h and (D) CASP1, 2 and 24 h.
TAC, TaqMan array cards.
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Figure5 Sp1 is a regulator of ERb-mediated gene expression and function in uterine ECs. (A) Bioinformatics analysis usingMetacoreTM revealed that 12
out of 18 ERb-dependent genes identiﬁed inHEECs have known associationswith the transcription factor Sp1.Metacore software utilizes some alternative
gene names: S1P1 receptor (ECGF), PD-ECGF (platelet derived ECGF), prostacyclin receptor (PTGIR), IP10 (CXCL10), ESR2 (ERb), ERK1 (MAPK3), THAS
(TBXAS1), PEDF (SERPINF1), SDF1 (CXCL12). (B)Western blot analysis of nuclear extracts fromall four cell lines using antibodies speciﬁc for Sp1 (81 KDa)
and the endogenous controlb lamin (68 KDa); lane 1, Ishikawa cells; lane 2, HUVEC; lane 3, HEEC; lane 4, UtMVEC; M, Marker. (C) Sp1 was detected by
immunoblotting (IB) with Sp1-speciﬁc mousemonoclonal antibody. HEECs treated with DMSO (lane 1) or 1028 MDPN (lane 2) for 24 h and after immu-
noprecipitation (IP) with an anti-ERb rabbit polyclonal antibody in HEECs treated with DMSO (lane 5) or DPN (lane 6). No Sp1 was detected in HEECs
immunoprecipitatedwith rabbit IgG (lane 3) or in the cross-linked IP sample (lane 4). (D) Knockdown of Sp1 in HEECswas achieved following transfection
with a Sp1-speciﬁc siRNA (white bars) in the presence or absence of DPN for 24 h; control scrambled siRNA is shownwith blue bars. qPCR analysis con-
ﬁrmed knockdown efﬁciency: 61% in DMSO-treated samples and 67%DPN-treated samples. (E, F) Knockdown of Sp1 (white bars) in HEECs abrogated
the signiﬁcant impact of DPN (*P,0.05, **P,0.01, ***P,0.001). on the expression ofHEY1 (E) and IFNb1 (F), respectively (G) Network formation assay
usingHEECs showing that incubationwithMithramycin A (50 nM) rescued theDPN-mediated decrease in network formation. MA,Mithramycin A. n ¼ 6.
(H) Representative images for the different treatments reported in (G). Scale bar is 100 mm.
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natural and synthetic estrogens on EC function needs to be conducted in
models appropriate to the target tissue. Finally, this is the ﬁrst study to
suggest a role for Sp1 in ERb-dependent changes in uterine EC function.
Binding of liganded ERb to Sp1 sites has been shown in cells expressing
endogenous levels of ERb (Vivar et al., 2010), and Sp1 has previously
been implicated in uterine cell-speciﬁc expression of the HOXA10
gene in response to estrogen (Martin et al., 2007). However, this is the
ﬁrst study highlighting an important role for Sp1 in ERb-directed tran-
scription in ECs and drawing attention to the importance of
ERE-independent, ‘tethered’ mechanisms in estrogen regulation of
gene expression (Nilsson et al., 2001). Further studies are now
merited to explorewhether targeting Sp1-ERb-dependent gene expres-
sion offers an alternative treatment option for targeting speciﬁc cell types
in reproductive pathologies.
ERb induces contrasting effects on uterine
vascular function
There have been reports that myometrial ECs are heterogeneous in
nature, that a subpopulation express ERa and ERb and that ERa agonists
promote angiogenesis in these cells (Zaitseva et al., 2004).We have not
ﬁnd this to be the case in present or past studies using full-thickness bi-
opsies of normal human uteri; the myometrial EC model (UtMVECs)
used in this study did not express ERa. Our robust characterization of
ECs both in situ and in our chosen models failed to detect either ERa
mRNA or protein in the EC lines. Of particular interest, was our
ﬁnding that the ERb-selective agonist, DPN, decreases network forma-
tion in endometrial ECs (HEECs). During the normal menstrual cycle,
there is a signiﬁcant increase in angiogenesis during the proliferative
phase that replenishes the vascular bed. Although it may be presumed
that E2 levels are responsible, the direct or indirect mechanism of the
regulation of angiogenesis remains uncertain (Girling and Rogers,
2005).Theendometrium is acomplexmulti-cellular tissueandwespecu-
late that in vivo, an E2-dependent increase in angiogenesis may be
mediated via ERa-positive cells such as perivascular cells, stromal ﬁbro-
blasts or epithelial cells. For example, vascular endothelial growth factor
(VEGF)mRNAhas been shown to increase in stromal and epithelial cells
of the endometrium in baboons supplemented with estrogen (Niklaus
et al., 2003). In support of this idea, it has been reported that there is
an increase in network formation when uterine microvascular cells are
co-cultured with epithelial cells treated with E2 (Albrecht et al., 2003).
Targeted gene proﬁling of angiogenesis factors in each uterine cell line
was consistent with observations made in functional assays. In HEECs,
pro-angiogenic growth factors were down-regulated, a ﬁnding which
correlated with the decrease in network formation. In UtMVECs,
there was a general up-regulation in pro-angiogenic factors and down-
regulation in inhibitors, corresponding with the identiﬁed increase in
network formation.
Surprisingly, we found that DPN caused a decrease in angiogenesis
in HEECs while E2 had no effect. DPN consistently had a strikingly
more potent effect on HEEC and UtMVEC network formation
than the naturally occurring ligand E2. Additionally, gene expression
analysis revealed that treatment of cells with DPN often had a differ-
ent impact to E2. The planar ligand DPN is both ERb afﬁnity and
potency selective (Meyers et al., 2001). The speciﬁc chemical struc-
ture of DPN means that it docks in the LBD of ERs differently from
E2 (Sun et al., 2003). Because of these structural differences, these
two agonists induce ligand-speciﬁc changes in receptor conformation
(Leitman et al., 2010), precipitating recruitment of different
co-regulatory molecules. The nature of the estrogenic ligand is,
therefore, the driving force of the composition of co-regulatory com-
plexes, and ultimate ligand-speciﬁc gene expression and biological
response ensues (Nilsson et al., 2011). Our results appear to
mirror those in a previous study that compared changes in response
to activation of ERb by the natural product liquiritigenin and those
induced by E2 and found only a few common candidates, prompting
the authors to state that different ERb agonists may produce distinct
biological effects (Paruthiyil et al., 2009). Their study in combination
with ours, reporting speciﬁc functional effects of DPN on uterine
angiogenesis may inform the future use of selective estrogen recep-
tor modulators. If an ERb-selective agonist can be used to treat
endometrial disorders, this would be preferential to the current ther-
apies using GnRH analogues as it would avoid some of the side-
effects of an induced hypoestrogenic state.
ECmodels possess unique ERb proﬁles
Targeted gene proﬁling revealed striking differences in the response of
the three EC lines analyzed with very few shared candidates observed.
Regulation of three common genes was detected: HEY1, ICAM1, and
CASP1. While the two uterine EC lines exhibited very different expres-
sion proﬁles, the HUVEC proﬁle was comparatively unique from either
of the other ECs. This reiterates that although HUVECs are used as a
commonmodel of vascular function, they do not represent an appropri-
ate substitute in the context of the uterus. Additional genes regulated in
the two uterine cell lines were IFNB1 and ENPP2. ENPP2 has previously
been identiﬁed as a primary ERb target gene using chromatin immuno-
precipitation in HEK293 (embryonic kidney) cells engineered to over-
express ERb (Zhao et al., 2009). In studies proﬁling ERb-dependent
genes in malignant cell lines, ENPP2 was one of the few common
genes identiﬁed (Monroe et al., 2003). In addition to ICAM1, ITGB2 (in-
tegrin beta 2) was also regulated in HEECs and UtMVECs, consistent
with a role for estrogens in the regulation of vascular permeability
(Cho et al., 1998). A number of protein families had members that
were regulated in two or all of the EC lines. We found that the expres-
sion of genes associated with prostaglandin metabolism was altered in
all three ECs. In HEECs, thromboxane A synthase 1 (TBXAS1) and pros-
taglandin I2 receptor (PTGIR) were reduced, in UtMVECs thromboxane
A2 receptor (TBXA2R) was increased and, in HUVECs, the cyclooxy-
genase enzymes (PTGS1 and PTGS2) and TBXAS1 were all reduced.
Estrogen regulates prostanoid synthesis in the placental vasculature
(Su et al., 2011) and up-regulates the expression of PTGS1 via ERb in
a mixed population of uterine microvascular cells (Tamura et al.,
2004). Our results indicate that prostanoid biosynthesis is ERb regu-
lated in all three ECs, albeit at different steps of the pathway, and pos-
sibly with differing outcomes.
ERbmediates changes in transcription in
endometrial ECs via non-classical ER signaling
involving the Sp1 transcription factor
In an extension of our observations on gene expression, we also used re-
porter assays to demonstrate that ERb was unable to induce transcrip-
tion via binding to classical EREs in uterine ECs. This ﬁnding was
consistent with the results obtained by another group performing
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studies in HUVECs: they concluded that these cells lacked estrogen re-
sponsiveness (Jensen et al., 1998), while our studies have shown this is
not the case. Bioinformatic analysis revealed that many of our identiﬁed
ERb-dependent gene candidates in HEECs had known associations with
the transcription factor Sp1. Using immunoprecipitation, we found that
ERb and Sp1 co-exist in a complex in HEECs.We found that the associ-
ation was not dependent on ligand (DPN) binding to ERb indicating that
the protein complex is pre-formed within the nucleus. Consistent with
this hypothesis, our unpublished studies and another report (Muyan
et al., 2012) have shown that in the absence of ligand, the ERb protein
appears less mobile within the nucleus than ERa suggesting that ERb is
already bound to chromatin regardless of the presence of ligand. As an
extension of these ﬁndings, we determined whether Sp1 was essential
or dispensable for ERb-dependent changes in gene expression and EC
function by using both Mithramycin A, an inhibitor of Sp binding to
GC-rich promoter sequences and Sp1-speciﬁc siRNA knockdown.
Sp1 and ERb were both found to be essential for DPN-dependent
changes in angiogenesis (network formation) and we therefore suggest
thatDPN induces a conformation in ERb that favours changes in gene ex-
pression via a ‘tethered’ Sp1-dependent mechanism (Nilsson et al.,
2001) in endometrial ECs.
Summary
Taken together, gene expression analysis of HEECs, UtMVECs and
HUVECs in response to DPN demonstrated: (i) very few common
genes but a deﬁned set of unique regulated genes in each cell line;
(ii) common genes in HEECs and UtMVECs being regulated in opposing
directions; (iii) a general down-regulation of pro-angiogenic factors in
HEECs, but a general down-regulation of angiogenesis inhibitors in
UtMVECs and (iv) that the latter correlates with the results of functional
angiogenesis assays.Moreover, ERb-mediatedchanges in geneexpression
inHUVECswere not similar to that inHEECs orUtMVECs, indicating that
this EC type is not suitable for modeling the impacts of ligand-binding ERb
in uterine vascular function. Finally, we showed (v) that the transcription
factor Sp1 is required in HEECs for ERb-dependent changes in gene ex-
pression associated with angiogenesis to take place.
Uterine ECmodels represent paradigms in
anatomically diverse microvascular function
We propose that uterine ECs represent good models in which to inves-
tigate the potential impacts of ligands capable of high-afﬁnity binding to
ERb in health and disease. Notably, these cells do not express ERa in
vivo or in vitro and so estrogen action must be mediated via ERb alone.
Endometrial ECswere obtained froma tissue subject to cyclical regener-
ation and the formation of newblood vessels, a quality rare inmost adult
tissues, the exception being those subject to malignant transformation.
We have demonstrated that the ERb activation in HEECs induces a de-
crease in network formation by these cells consistent with a reduction in
the rate of angiogenesis. In contrast, although also exposed to ﬂuctuating
concentrations of estrogens, the vasculature of the normal myometrium
is relatively inert although it may be disturbed by the presence of uterine
ﬁbroids. We observed an increase in angiogenesis in myometrial ECs in
response to ERb activation, which might complement previous ﬁndings
that ERb signalingmayhave positive effects on angiogenesiswithin quies-
cent tissues.Our results suggest that ERb agonists, both natural, e.g. gen-
estein, and synthetic, e.g. 8b-VE2 and ERb-041, may have unique
cell-speciﬁc impacts in cells expressing ERb alone. Although further func-
tional studies are required to validate the therapeutic potential of the
above ﬁndings, the results presented here may have implications for
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